#USA #New York #Faruqi & Faruqi #securities litigation #Rocket Pharmaceuticals

Investors of Rocket Pharmaceuticals Urged to Take Action

As the deadline for legal claims approaches, investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) who have incurred losses exceeding $50,000 between February 27, 2025, and May 26, 2025, are being encouraged to seek legal representation. Faruqi & Faruqi, LLP, a prominent national securities law firm, is investigating potential claims against the company and highlights the urgency of acting before the August 11, 2025, cut-off for filing as a lead plaintiff in a federal securities class action.

Overview of the Situation

Faruqi & Faruqi's Securities Litigation Partner James (Josh) Wilson stated, "We are committed to assisting investors who have suffered significant losses due to the actions of Rocket Pharmaceuticals." The firm is particularly focused on claims arising from misleading statements made by Rocket regarding the safety and clinical trial protocols of their product RP-A501. According to the complaint, the company made positive public statements while concurrently concealing crucial information about the risks associated with the drug, which included severe adverse events (SAEs).

In an alarming revelation, it came to light that Rocket Pharmaceuticals failed to disclose that an amendment was made to the RP-A501 trial protocol, which introduced a novel immunomodulatory agent without informing investors at the time of the change. This lack of transparency may have contributed to inflated share prices, causing investors to buy into the company under false pretenses.

The Impact of Recent Developments

On May 27, 2025, Rocket revealed that the FDA had placed a clinical hold on the RP-A501 Phase 2 pivotal study following a Serious Adverse Event that resulted in a participant's death. This announcement led to a dramatic decline in the company’s stock price, falling from a closing price of $6.27 on May 23 to $2.33 just four days later, marking a staggering 37% drop in value.

The fallout from the announcement raised significant concerns among investors, prompting many to explore their legal options. This situation underscores the importance of understanding shareholders' rights and the potential for recovery following such incidents.

What Investors Should Do

Investors who believe they have standing to file a claim are urged to reach out to Faruqi & Faruqi, LLP directly. They can contact Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for a confidential consultation.

Faruqi & Faruqi also welcomes any information about Rocket's actions from whistleblowers, former employees, and others who may have insights into the company's practices.

Final Thoughts

With the August deadline rapidly approaching, time is of the essence for Rocket Pharmaceuticals' investors. By taking proactive steps now, affected shareholders can potentially join together to seek redress. For more information regarding the ongoing investigation and class action details, visit Faruqi & Faruqi's website.

By staying informed and engaged with legal counsel, investors can safeguard their rights and pursue the compensation they rightfully deserve.